LEXINGTON, Mass., Feb. 21, 2012 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a drug development company seeking to develop proprietary targeted medicines for cancer treatment, today announced that the Company will be presenting at the 2012 RBC Capital Markets' Healthcare Conference at 1:35 p.m. EST on February 28, 2012, in New York City.
Dan Passeri, President and Chief Executive Officer, will provide an overview of Erivedge™ (vismodegib), a hedgehog pathway inhibitor under collaboration with Genentech, a member of the Roche Group. Erivedge is the first FDA-approved medicine for people with advanced forms of basal cell carcinoma. Mr. Passeri will also provide an overview of Curis' other network-targeted cancer programs including CUDC-101, CUDC-907 and Debio 0932, as well as discuss other corporate activities.
A corresponding webcast of the presentation can be accessed by visiting:
http://www.wsw.com/webcast/rbc141/cris/
The presentation will be archived shortly after the live event and available for 30 days following the conference. In addition, it will be available for 30 days on the Investor Relations section of the Curis website at www.curis.com.
About Curis, Inc.
Curis is a drug development company that is committed to leveraging its innovative signaling pathway drug technologies to seek to create new targeted small molecule drug candidates for cancer. Curis is building upon its previous experiences in targeting signaling pathways, including in the Hedgehog pathway, in its effort to develop proprietary targeted cancer programs. For more information, visit Curis' website at www.curis.com.
The Curis, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=11347
CONTACT: For More Information:
Michael P. Gray
CFO & COO
Curis, Inc.
617-503-6632
mgray@curis.com